胸段硬膜外麻醉在心脏手术中的系统评价、荟萃分析与试验序贯分析
该系统评价与荟萃分析纳入51项随机对照试验(2112例胸段硬膜外麻醉患者和2220例单纯全麻患者),评估胸段硬膜外麻醉在心脏手术中的获益与风险。结果显示胸段硬膜外麻醉显著缩短ICU停留时间、住院时间和拔管时间,并减少疼痛评分、肺部并发症、输血需求、谵妄和心律失常,且硬膜外血肿风险估计低于0.14%。
要点
- 胸段硬膜外麻醉缩短心脏手术患者ICU停留时间、住院时间和拔管时间。
- 胸段硬膜外麻醉降低疼痛评分、肺部并发症、输血需求、谵妄和心律失常。
- 硬膜外血肿风险估计低于0.14%,安全性顾虑可能被高估。
核心结论
- 胸段硬膜外麻醉可缩短心脏手术患者ICU和住院时间并减少术后并发症,硬膜外血肿等并发症报告极少,支持在心脏手术中使用胸段硬膜外麻醉。
研究设计与样本
- 系统评价与荟萃分析,检索4个数据库截至2022年6月4日的随机对照试验,比较成人心脏手术中胸段硬膜外麻醉联合全麻与单纯全麻。
- 纳入51项随机对照试验,共2112例胸段硬膜外麻醉患者和2220例单纯全麻患者。
- 采用随机效应模型进行荟萃分析,使用Cochrane Risk-of-Bias 2工具评估偏倚风险,通过GRADE方法评级证据确定性,并对所有结局进行试验序贯分析。
主要发现
- 胸段硬膜外麻醉对死亡率无显著影响;试验序贯分析显示ICU停留时间、住院时间和拔管时间的累积Z曲线跨越TSA调整边界,提示临床获益。
- 胸段硬膜外麻醉显著降低疼痛评分、汇总肺部并发症、输血需求、谵妄和心律失常,硬膜外血肿风险估计低于0.14%。
临床怎么用
- 对于接受心脏手术的成人患者,可考虑采用胸段硬膜外麻醉联合全麻以加速术后恢复。
- 实施胸段硬膜外麻醉时应权衡硬膜外血肿风险,尽管本分析估计该风险低于0.14%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Research on fast-track recovery protocols postulates that thoracic epidural anesthesia (TEA) in cardiac surgery contributes to improved postoperative outcomes. However, concerns about TEA's safety hinder its widespread usage. We conducted a systematic review and meta-analysis to assess the benefits and risks of TEA in cardiac surgery. METHODS: We searched 4 databases for randomized controlled trials (RCTs) assessing the use of TEA against only general anesthesia (GA) in adults undergoing cardiac surgery, up till June 4, 2022. We conducted random-effects meta-analyses, evaluated risk of bias using the Cochrane Risk-of-Bias 2 tool, and rated certainty of evidence via the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach. Primary outcomes were intensive care unit (ICU), hospital length of stay, extubation time (ET), and mortality. Other outcomes included postoperative complications. Trial sequential analysis (TSA) was conducted on all outcomes to elicit statistical and clinical benefit. RESULTS: Our meta-analysis included 51 RCTs (2112 TEA patients and 2220 GA patients). TEA significantly reduced ICU length of stay (-6.9 hours; 95% confidence interval [CI], -12.5 to -1.2; P = .018), hospital length of stay (-0.8 days; 95% CI, -1.1 to -0.4; P < .0001), and ET (-2.9 hours; 95% CI, -3.7 to -2.0; P < .0001). However, we found no significant change in mortality. TSA found that the cumulative Z-curve passed the TSA-adjusted boundary for ICU length of stay, hospital length of stay, and ET, suggesting a clinical benefit. TEA also significantly reduced pain scores, pooled pulmonary complications, transfusion requirements, delirium, and arrhythmia, without additional complications such as epidural hematomas, of which the risk was estimated to be <0.14%. CONCLUSIONS: TEA reduces ICU and hospital length of stay, and postoperative complications in patients undergoing cardiac surgery with minimal reported complications such as epidural hematomas. These findings favor the use of TEA in cardiac surgery and warrant consideration for use in cardiac surgeries worldwide.
引用
- Chiew JK, Low CJW, Zeng K, et al. Thoracic Epidural Anesthesia in Cardiac Surgery: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis of Randomized Controlled Trials. Anesth Analg. 2023. PMID: 37220070. doi:10.1213/ANE.0000000000006532
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。